Hope is on the horizon for needle-phobic patients as Griffith University researchers have created a new influenza vaccine ...
The FDA agreed for Novavax to continue trials of its vaccine combo after addressing a serious adverse event that paused ...
Hope is on the horizon for needle-phobic patients as Griffith University researchers have created a new influenza vaccine ...
On Monday, the FDA removed the clinical hold on Novavax Inc.’s (NASDAQ:NVAX) Investigational New Drug (IND) application for ...
The FDA had put a clinical hold on Novavax’s COVID-19-influenza combo vaccine after an adverse event in a patient. The U.S.
The Food and Drug Administration has lifted its clinical hold on a late-stage trial of Novavax's COVID-influenza and its ...
The FDA has lifted its clinical hold on Novavax's combined COVID-19 and influenza vaccine trial, finding no link between the ...
Gaithersburg: Novavax, Inc., a global company advancing protein-based vaccines with its Matrix-M adjuvant, has announced that ...
In its recent third-quarter 2024 earnings report, Novavax highlighted significant advancements in its vaccine portfolio, including the removal of a clinical hold by the U.S. FDA on its ...
Novavax is already poised to benefit from a separate combined Covid-flu vaccine via a deal with Sanofi announed earlier this year. Under the $1.4 billion co-licensing agreement, announced in May, ...
The latest update is out from Novavax ( (NVAX)). Novavax, a leader in vaccine development, announced the FDA’s removal of a clinical hold on their COVID-19-Influenza combination and influenza vaccine ...
Novavax received clearance from the FDA to move forward with phase 3 clinical trials for its COVID-19-influenza combination (CIC ... confirming that the event was not related to the investigational ...